Attached files
| file | filename |
|---|---|
| 8-K - China Botanic Pharmaceutical | v204449_8k.htm |
|
Company
Contact:
|
CCG
Investor Relations:
|
|
China
Botanic Pharmaceutical Inc.
|
Mr.
Mark Collinson, Partner
|
|
Ms.
Portia Tan, IR Contact
|
Phone:
+1-310-954-1343 (Los Angeles)
|
|
Tel:
86-451-8260-2162
|
Email:
mark.collinson@ccgir.com
|
|
Email:
ir@renhuang.com
|
Website:
www.ccgirasia.com
|
|
Mr.
Crocker Coulson, President
|
|
|
Phone:
+1-646-213-1915 (New York)
|
|
|
Email:
crocker.coulson@ccgir.com
|
For
Immediate Release
Renhuang
Pharmaceuticals Announces Name Change to China Botanic Pharmaceutical
Inc.
Harbin, China – November
29,
2010 – China Botanic Pharmaceutical Inc. (NYSE Amex: CBP) (“China
Botanic” or the “Company”), a developer, manufacturer and distributor of
botanical products, bio-pharmaceuticals and traditional Chinese medicines
(“TCM”), today announced that the Company’s Articles of Incorporation have been
amended to effect the name change of the Company from its former name of
Renhuang Pharmaceuticals.
China
Botanic noted that after four years it is retiring the name Renhuang
Pharmaceuticals and will now officially be known as China Botanic Pharmaceutical
Inc. to better reflect the Company’s corporate identity, brand image and
business operations. The legal structure of China Botanic remains
unchanged.
"We are a
rapidly growing and expanding botanic and bio-pharmaceutical company and we
believe our new corporate name better reflects our business operations and
product portfolio,” said Mr. Shaoming Li, the Chairman and CEO of China Botanic
Pharmaceutical Inc. “We believe our new name – China Botanic Pharmaceutical Inc.
can be easily associated with our brand promise and our product categories, and
will be well accepted in our target markets. We are actively expanding sales
beyond our leading Siberian Ginseng products and introducing new products to
drive future revenue and net income growth. We believe this is a good time to
set the stage for our new corporate and brand entity.”
ABOUT
CHINA BOTANIC PHARMACEUTICAL INC.
China
Botanic Pharmaceutical Inc. is engaged in the research, development,
manufacturing, and distribution of botanical products, bio-pharmaceutical
products, and traditional Chinese medicines ("TCM"), in the People's Republic of
China. All of the Company's products are produced at its three
GMP-certified production facilities in Ah City, Dongfanghong and Qingyang. The
Company distributes its botanical anti-depression and nerve-regulation products,
biopharmaceutical products, and botanical antibiotic and OTC TCMs through its
network of over 3,000 distributors and over 70 sales centers across 24 provinces
in China.
Safe
Harbor Statement
This
press release contains certain statements that may include forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of
1995. Such statements are based upon management’s beliefs, assumptions and
expectations of the Company’s future operations and economic performance, taking
into account the information currently available to management. These statements
are not statements of historical fact. Forward-looking statements involve risks
and uncertainties, some of which are not currently known that may cause actual
results, performance or financial condition to be materially different from the
expectations of future results, performance or financial condition expressed or
implied in any forward-looking statements. These forward-looking statements are
based on current plans and expectations and are subject to a number of
uncertainties including, but not limited to, the Company’s ability to
achieve its financial guidance, ability to manage expansion of its operations
effectively, competition in the marketing and sales of its products, and other
factors detailed in the Company’s annual report on Form 10-K and other filings
with the Securities and Exchange Commission. The Company undertakes no
obligation to publicly update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise. You are cautioned
not to unduly rely on such forward-looking statements when evaluating the
information presented herein.
###